Next Article in Journal
New Insights into Neutrophil Extracellular Trap (NETs) Formation from Porcine Neutrophils in Response to Bacterial Infections
Previous Article in Journal
High-Depth Transcriptome Reveals Differences in Natural Haploid Ginkgo biloba L. Due to the Effect of Reduced Gene Dosage
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 23
Issue 16
10.3390/ijms23168959
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Activation of cAMP Signaling in Response to α-Phellandrene Promotes Vascular Endothelial Growth Factor Levels and Proliferation in Human Dermal Papilla Cells

by
Wesuk Kang
†,
Soyoon Park
†,
Dabin Choi
,
Bomin Son
and
Taesun Park
*
Department of Food and Nutrition, BK21 FOUR, Yonsei University, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-749, Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2022, 23(16), 8959; https://doi.org/10.3390/ijms23168959
Submission received: 13 July 2022 / Revised: 8 August 2022 / Accepted: 10 August 2022 / Published: 11 August 2022
(This article belongs to the Section Biochemistry)
Browse Figures
Versions Notes

Abstract

:
Dermal papilla cells (DPCs) are growth factor reservoirs that are specialized for hair morphogenesis and regeneration. Due to their essential role in hair growth, DPCs are commonly used as an in vitro model to investigate the effects of hair growth-regulating compounds and their molecular mechanisms of action. Cyclic adenosine monophosphate (cAMP), an intracellular second messenger, is currently employed as a growth-promoting target molecule. In a pilot test, we found that α-phellandrene, a naturally occurring phytochemical, increased cAMP levels in DPCs. Therefore, we sought to determine whether α-phellandrene increases growth factors and proliferation in human DPCs and to identify the underlying mechanisms. We demonstrated that α-phellandrene promotes cell proliferation concentration-dependently. In addition, it increases the cAMP downstream effectors, such as protein kinase A catalytic subunit (PKA Cα) and phosphorylated cAMP-responsive element-binding protein (CREB). Also, among the CREB-dependent growth factor candidates, we identified that α-phellandrene selectively upregulated vascular endothelial growth factor (VEGF) mRNA expression in DPCs. Notably, the beneficial effects of α-phellandrene were nullified by a cAMP inhibitor. This study demonstrated the cAMP-mediated growth effects in DPCs and the therapeutic potential of α-phellandrene for preventing hair loss.

1. Introduction

Hair loss is a result of hair thinning. The dermal papilla (DP), which is located at the base of the hair follicle, plays a crucial role in regulating hair shaft thickness [1,2,3]. The roles of growth factors in this process have received considerable attention recently. Growth factors can stimulate the cells surrounding the hair follicle, such as the endothelial and epithelial cells, to vigorously proliferate and differentiate, which could contribute to thickening hair shafts and promoting hair growth [4,5,6]. Although hair follicles are composed of more than 20 types of cells, DP cells (DPCs) are generally regarded as a key player in growth factor production and supply to the hair follicle [1,7,8,9]. These growth factors also stimulate the producer cell itself to proliferate rapidly, which could ultimately result in growth factor regeneration. Therefore, increasing growth factor secretion in DPCs has been considered a promising strategy to prevent and treat hair loss [10,11,12,13,14].
Therapeutic targets for boosting growth factors have been studied continuously for several decades. G-protein-coupled receptors (GPCRs), which are located on the cell surface, have gained pharmacological interest as an attractive molecular target due to their ubiquity and easy accessibility to extracellular molecules. Indeed, the vast majority of the US Food and Drug Administration (FDA)-approved drugs (~40%) exert their effects by activating the GPCR-mediated cyclic adenosine monophosphate (cAMP) pathway [15,16]. For example, adrenergic receptor agonist-induced cAMP accumulation enhances vascular endothelial growth factor (VEGF) gene expression in various cells, including brown adipocytes, cardiac myocytes, and macrophages [17,18,19]. We have previously reported that elevated intracellular cAMP levels by several phytochemicals (e.g., cedrene and nonanal) upregulate several growth factors, including insulin-like growth factor-1 (IGF-1) in myoblasts and DPCs, which is significantly ameliorated by cAMP inhibitors [20,21]. Although it has not been clearly established, several recent studies have shown that cAMP-dependent growth factor gene expression regulation is potentially associated with protein kinase A (PKA) and its downstream effectors, cAMP-responsive element-binding protein (CREB) [20,22,23].
Currently, two synthetic chemicals, minoxidil and finasteride, are exclusively approved by the FDA and considered the main options for treating hair loss. However, due to their side effects, including eczema, ejaculatory dysfunction, and cognitive symptoms, there has been steady progress in the development of novel hair growth promoters from natural compounds [24,25,26]. We attempted to find a potential biocontrol agent that has been empirically applied in several fields, such as cosmetics and food additives. α-Phellandrene, found in essential oils such as eucalyptus, lavender, and geranium, is approved as a safe flavoring agent by credible organizations, including the FDA, the Joint Food and Agriculture Organization of United Nations (FAO)/World Health Organization (WHO) Expert Committee on Food Additives (JECFA), and Flavor Extract Manufacturers Association (FEMA). It has been widely used in commercial applications, such as cosmetics, detergents, and perfumes because of its characteristic aroma. It is also regarded as a bioactive molecule receiving considerable scientific attention due to its broad-spectrum physiological functions, such as anti-nociceptive, anti-inflammatory, and anti-antimicrobial effects in vitro and in vivo [27,28,29,30]. This study aimed to determine whether α-phellandrene activates the cAMP signaling pathway and whether this compound influences proliferation and growth factors via the cAMP pathway in DPCs.

2. Results

2.1. α-Phellandrene Increases cAMP Levels in DPCs

cAMP signaling can promote cell proliferation; thus, we attempted to identify the molecules that increase cAMP levels in DPCs. We found that α-phellandrene significantly increased cAMP levels in a concentration-dependent manner, with the half-maximal effective concentration (EC50) being 5.9 μM (Figure 1A,B). Additionally, we confirmed that forskolin, a well-known cAMP stimulator, also induced cAMP accumulation in a dose-dependent manner (Figure 1C).

2.2. α-Phellandrene Promotes DPC Proliferation

We further determined whether α-phellandrene stimulates DPC proliferation at 24, 48, and 72 h after treatment using a Water-Soluble Tetrazolium Salt (WST-1) assay. Considering that α-phellandrene exhibited potent cAMP-elevating activity with EC50 of 5.9, and that the EC50 value is often used as a reference for the critical concentration of chemical compounds required for their significant action, we hypothesized that its physiological effects may begin to manifest at least over 5.9 μM. Thus, DPCs were cultured in the presence of vehicle control (dimethyl sulfoxide; DMSO) or five different concentrations of α-phellandrene (6.25, 12.5, 25, 50, and 100 µM). α-phellandrene significantly increased DPC proliferation in a concentration-dependent manner, and this effect appeared to be saturated at 12.5 µM. On the other hand, forskolin treatment (10 µM) significantly decreased DPC proliferation (Figure 2). To investigate the effect of α-phellandrene on cell death, the DPCs were treated with either vehicle control (DMSO) or various concentrations of α-phellandrene (12.5–1200 μM). Treatment of α-phellandrene at concentrations as high as 600 μM did not cause cell death, and cytotoxicity was observed to occur after treatment with 800 μM or more of α-phellandrene (Figure S1).

2.3. cAMP Accumulation by α-Phellandrene Leads to the Stimulation of Downstream PKA/CREB Signaling in DPCs

We also examined whether α-phellandrene regulates the cAMP downstream effectors, such as PKA catalytic subunit (PKA Cα) and phosphorylated CREB in DPCs. α-phellandrene upregulated both PKA Cα expression and CREB phosphorylation level in a time-dependent manner, and significant increases were observed after 0.5 h (Figure 3A,B).
To further investigate whether the changes in PKA/CREB signaling were involved in the α-phellandrene-induced increase in cAMP levels, we measured PKA Cα expression and CREB phosphorylation level in the presence of 50 µM of SQ22,536. Exposure to SQ22,536 significantly decreased PKA Cα expression and CREB phosphorylation level in α-phellandrene-treated DPCs (Figure 3C,D).

2.4. α-Phellandrene Promotes Cell Proliferation via the cAMP Signaling Pathway

To exclude the possibility that α-phellandrene might promote cell proliferation through an alternative pathway, we evaluated the proliferative effect of α-phellandrene in the presence of 50 µM of SQ22,536, 10 µM of H89, or 100 nM of 666-15. All these inhibitors completely blocked α-phellandrene-induced DPC proliferation (Figure 4A–C), suggesting that α-phellandrene promotes cell growth through cAMP signaling in DPCs.

2.5. α-Phellandrene Increases VEGF Gene Expression in DPCs

Since it is well known that the proliferation capacity of DPC is actively modulated by various growth factors, we hypothesized that α-phellandrene-induced cell proliferation is associated with the increased expression of certain growth factors. Accordingly, we listed the growth factor or growth-related genes expressed in DPCs, and then, considering that the effect of α-phellandrene was mediated through the cAMP/PKA/CREB pathway, we limited the potential genes responsible for α-phellandrene-induced cell proliferation to CREB target genes using hTFtarget (a comprehensive database for the human transcription factors and their targets). Finally, eighteen candidate genes were derived, and their mRNA expression in response to α-phellandrene treatment was analyzed [31,32,33,34,35]. These growth-related genes are as follows: bone morphogenetic protein 1 (BMP1), colony stimulating factor 1 (CSF1), fibroblast growth factor 1 (FGF1), fibroblast growth factor 11 (FGF11), glial cell derived neurotrophic factor (GDNF), glucose-6-phosphate isomerase (GPI), heparin binding epidermal growth factor- like growth factor (HBEGF), insulin-like growth factor 1 (IGF1), inhibin subunit beta A (INHBA), notch ligand jagged-1 (JAG1), midkine (MDK), nerve growth factor (NGF), neurotrophin 3 (NTF3), neuregulin 1 (NRG1), platelet-derived growth factor C (PDGFC), secreted phosphoprotein 1 (SPP1), transforming growth factor beta 1 (TGFB1), and VEGF. Among these, only VEGF expression significantly increased by α-phellandrene treatment (Figure 5A). We also verified that the stimulatory effect of phellandrene on VEGF mRNA expression did not show after 3 h of treatment, but became evident after 6 h of treatment and persisted after 12 h of treatment (Figure 5B).

2.6. The Inhibition of the cAMP Pathway Blocks the Effect of α-Phellandrene on VEGF Production

To determine whether α-phellandrene-induced VEGF production was mediated via the cAMP pathway, DPCs were treated with α-phellandrene with or without 50 µM of SQ22,536 (cAMP inhibitor). VEGF mRNA in cells was assessed and VEGF protein in media was also determined. SQ 22536 treatment completely inhibited VEGF mRNA expression in α-phellandrene-treated DPCs (Figure 6A). In line with mRNA expression, α-phellandrene significantly increased VEGF secretion from DPCs, which was blocked by SQ 22536 treatment (Figure 6B). Taken together, cAMP pathway stimulation by α-phellandrene is a possible mechanism for promoting DPC proliferation and VEGF expression (Figure 7).

3. Discussion

Topical delivery of agent is an efficient alternative to traditional methods, including parenteral and oral deliveries: Benefits related to the topical route include first-pass metabolism bypass, reduced systemic toxicity/adverse events, and increased bioaccessibility and bioavailability due to the proximity to the target tissue [36,37,38]. Nevertheless, the outer skin serves as a barrier for large molecules due to the presence of stratum corneum (keratin-rich corneocytes embedded in lipid bilayers); therefore, only small (typically < 500 Dalton) and lipophilic molecules penetrate the inner dermis [39]. α-phellandrene is readily absorbed and reaches the DP layer by topical route due to its low molecular size (136.2 Dalton) and lipophilicity. We confirmed that α-phellandrene is more likely to be efficiently absorbed (permeability coefficient value (log Kp): −4.85 cm/s; increased log Kp allows molecule permeation) than other well-known topical agents for alopecia (minoxidil: −7.97 cm/s; caffeine: −7.53 cm/s) and other cutaneous diseases, such as atopic dermatitis (dexamethasone: −7.32 cm/s; tacrolimus: −7.88 cm/s) using an in silico tool for predicting skin absorption [40].
In this study, we experimentally found using a specific cAMP inhibitor that α-phellandrene increased VEGF levels via the cAMP signaling pathway in DPCs. cAMP signaling is usually followed by GPCR stimulation and further adenylyl cyclase (Adcy) stimulation, which converts ATP to cAMP [41,42,43]. Although α-phellandrene has been reported to possibly bind to two GPCRs (opioid receptor and muscarinic cholinergic receptor) [27], we confirmed that these receptors are poorly expressed in basal and α-phellandrene-treated DPCs through next-generation sequencing (fragments per kilobase of transcript per million mapped reads (FPKM) = 0, unpublished data). To explore the novel upstream GPCR as a molecular target of α-phellandrene in DPCs, we employed in silico target prediction tools for predicting the possible target candidates of this specific agent for further experimental confirmation [44,45,46]. These ligand-based target identification tools have recognized several GPCRs, including adenosine receptors, dopamine receptors, and adrenergic receptors as promising candidates, which are all expressed in DPCs and considered attractive targets for the positive regulation of growth factors in mammalian cells [47,48,49]. Characterizing the specific upstream GPCR responsible for the beneficial effects of α-phellandrene in DPCs would be a promising and challenging avenue for future studies.
In the present study, two agents (forskolin and α-phellandrene) were used to compare the impact of cAMP on cell proliferation. Notably, the EC50 value of the α-phellandrene (5.9 μM) is as low as that of the forskolin of (2.7 μM). A low EC50 value indicates that the test material has a 50% effect of the maximum effects although the concentration of the test material is low. Considering that forskolin is currently accepted as the most effective cAMP activator, it would be speculated that significant effects of α-phellandrene through cAMP synthesis could be accomplished at a relatively low concentration compared to the other compounds. Also, cAMP systems act in a concentration-dependent manner, particularly in fibroblasts/fibroblast-like cells. For example, a lower cAMP level (around 150% of that in the control) in cardiac fibroblasts promotes cell migration, whereas higher cAMP levels (over 200% of that in the control) inhibit cell migration [50]. Furthermore, physiologically increased cAMP levels (150% of that in the control) activate collagen production in dermal fibroblasts, whereas extremely high cAMP levels (15,000% of that in the control), over the physiological range, inhibit collagen production [51]. In line with previous studies, a modest 12.5 µM α-phellandrene-induced cAMP increase (140% of control) promoted DPC growth, whereas a 10 µM forskolin (direct and irreversible Adcy activator)-mediated excess cAMP increase (1320% of that in the control), significantly decreased cell growth.
CREB is a well-characterized transcription factor, whose activity is regulated in various cell types by Ser133 phosphorylation. Genome-wide studies indicate that CREB binds to a target sequence named the cAMP response element (CRE) located in many cellular gene promoters and regulates up to 5000 putative target genes [52,53,54]. It is noteworthy that the capacity of CREB to bind to a specific CRE is different among the cell types; thus, the CREB target gene family differs from one cell type to another [55,56]. For example, gene profiling assays showed that exposure to forskolin, a cAMP activator, reliably induced hundreds of target genes in embryonic kidney cells as well as primary hepatocyte or pancreatic cell cultures, but the sets of cAMP-responsive genes in each case were almost completely different [57]. There is no consensus on the exact mechanism for such a cell-specific target gene activation profile, but it has been suggested that CREB binding to its target CRE is affected by the cell-specific histone methylation status at gene promoters, based on the significant correlation between specific target gene expression and histone H3 Lys-4 methylation [55]. In our study using DPCs, among the putative eighteen CREB target growth factor genes, we found that only VEGF mRNA expression was selectively upregulated by the α-phellandrene-mediated modest cAMP increase.
VEGF is an important angiogenic factor that activates hair follicle growth, which disappears during the telogen phase [58]. The hair follicles of VEGF-overexpressing mice are bigger and more numerous than those of wild mice [59]. In addition, it has been established experimentally that VEGF acts as an autocrine growth factor on human DPCs through the VEGF receptor-2 (VEGFR2) [58,60]. In line with this investigation, various studies using DPCs have shown that minoxidil and other natural agents, such as Asiasari radix extract, Carthamus tinctorius extract, and Malva verticillata extract, boost VEGF levels in DPCs and subsequently promote cell proliferation [61,62,63,64]. Unfortunately, in an in vitro system with one cell type, the contribution of growth factors to hair growth could not be fully represented and assessed, with cellular proliferation being the only robust phenotypic marker for assessing the effects of growth factors. Although we confirmed that α-phellandrene-mediated cAMP signaling increases VEGF levels and cell proliferation, it is well known that cAMP also promotes proliferation via multiple other mechanisms [65,66]. Further investigation is required to examine whether the enhanced VEGF levels in DPCs are solely responsible for upregulating the proliferation in response to α-phellandrene.
In contrast, in an in vivo system, growth factors can play additional roles in preventing and treating hair loss in peripheral target tissues. Notably, VEGF can function in the epidermis, where it promotes keratin generation in hair via the enhancement of keratinocyte proliferation, differentiation, and migration [67]. In addition, VEGF not only acts on the keratinocytes in the epidermis, as its name suggests, but also works on the blood vessels, promoting blood circulation and new blood vessel formation around follicles, which provides nourishment for the growing and differentiating cells [59,68]. In vivo experimental models should be further developed and investigated to fully assess the VEGF-mediated effects of α-phellandrene on hair growth.

4. Materials and Methods

4.1. Cell Culture

Primary human follicle DPCs (55-year-old, Caucasian, females) isolated from the human dermis of the scalp were purchased from PromoCell (Heidelberg, Germany) and grown in DPC growth medium with supplement mix (PromoCell) and 1% penicillin-streptomycin (10,000 U/mL; Gibco; Grand Island, NE, USA) at 37 °C in a 5% CO2 humidified atmosphere. At 70% confluency, the cells were sub-cultured according to the PromoCell subcultivation protocol using the DetachKit (2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffer, trypsin/ethylenediaminetetraacetic acid (EDTA), and trypsin neutralization solution; PromoCell). Passages 3–5 of DPCs were used in this study.

4.2. cAMP Measurement

DPCs (20,000 cells/well) were plated in a 24-well plate and incubated with the vehicle (DMSO; Sigma-Aldrich; Seoul, Korea), α-phellandrene (0.1, 1, 5, 10, 50, and 100 μM; Sigma-Aldrich) or forskolin (0.1, 0.5, 1, 5, 10, and 50 μM; Sigma-Aldrich) dose-dependently for 30 min. Subsequently, the cells were washed in ice-cold HEPES buffer and harvested by centrifugation at 1800× g at 25 °C for 5 min. After the supernatants were removed, the pellets were extracted with 0.1 M of HCl. Then, the extracts were centrifuged at 15,000× g and 25 °C for 3 min, and the supernatants were collected. The amount of cAMP in the supernatants was measured using a direct cAMP enzyme-linked immunosorbent assay (ELISA) kit (Enzo Life Sciences; Farmingdale, NY, USA) according to the manufacturer’s protocol. The cAMP concentration in each sample was normalized to the total protein concentration measured using the Bradford assay (Bio-Rad; Hercules, CA, USA).

4.3. WST-1 Assay

DPCs (4000 cells/well) were seeded in a 96-well plate, cultured in medium for 24 h, and treated with vehicle (DMSO) as a control, 6.25, 12.5, 25, 50, and 100 μM of α-phellandrene dose-dependently, or 10 μM of forskolin. After 24, 48, or 72 h of treatment, the cells were incubated with the WST-1 solution (Sigma-Aldrich) diluted 1:10 in culture medium for 3 h. The absorbance was measured at 450 nm against a blank (without cells) using an M200 microplate reader (Tecan; Männedorf, Switzerland). To investigate the mechanism underlying the proliferative effect of α-phellandrene, adenylyl cyclase inhibitor SQ22,536 (50 μM, Sigma-Aldrich), PKA inhibitor H89 (10 µM, Sigma-Aldrich), or CREB inhibitor 666-15 (100 nM; Selleckchem; Houston, TX, USA) was added 1 h before 12.5 μM of α-phellandrene treatment. The proliferation percentage of cells was relatively determined by considering vehicle-only treated cells (control) as 100%.

4.4. Lactate Dehydrogenase (LDH) Assay

To assess α-phellandrene-induced cytotoxicity, the release of LDH into the culture supernatant was determined using an EZ-LDH assay kit (DoGenBio; Seoul, Korea) in accordance with the manufacturer’s instructions. Briefly, DPCs (4000 cells/well) were seeded in a 96-well plate, cultured in the medium for 24 h, and treated with various concentrations of α-phellandrene (12.5–1200 μM) for another 72 h. The supernatant medium (10 μL) for each sample was then transferred to a 96-well plate and incubated with the LDH reaction mixture (100 μL) for 1 h at 25 °C. To quantify the LDH concentration in the culture media, the absorbance (450 nm) was measured on an Infinite M200 microplate reader (Tecan).

4.5. RNA Isolation, Complementary DNA (cDNA) Synthesis, and Quantitative Polymerase Chain Reaction (qPCR)

DPCs (100,000 cells/well) were plated in a 6-well plate and cultured with vehicle or 12.5 μM of α-phellandrene for 6 h. When required, they were pretreated with SQ22,536 for 1 h before α-phellandrene treatment. The cells were harvested for RNA extraction using TRIzol reagent (Invitrogen; Carlsbad, CA, USA) according to the manufacturer’s protocol. In brief, the samples were treated with chloroform (20% of the final volume, Sigma-Aldrich), vortexed briefly, incubated at 25 °C for 5 min, and centrifuged at 12,000× g and 4 °C for 15 min. The aqueous phase was transferred to a new tube and an equal volume of isopropanol (Sigma-Aldrich) was added. The samples were incubated at 4 °C for 10 min and centrifuged at 12,000× g and 4 °C for 10 min. After the supernatants were removed, the pellets were washed in 70% ethanol, dried, and resuspended in nuclease-free water. Total RNA concentration was measured using a NanoDrop 2000 (Tecan), and cDNA was synthesized using SuperScript IV reverse transcriptase (Invitrogen) and oligo(dT) primer (Invitrogen) on a GeneMax thermal cycler (BIOER; Hangzhou, China). The cDNA was then used for qPCR with gene-specific primers using SYBR green supermix (Bio-Rad) on a CFX Connect Real-Time PCR Detection System (Bio-Rad). qPCR reactions were run at 57 °C annealing temperature for all primers. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the housekeeping gene for normalization. The primer sequences used for qPCR are presented in Supplementary Table S1.

4.6. Western Blot

DPCs (100,000 cells/well) were seeded in a 6-well plate and incubated with vehicle or 12.5 M of α-phellandrene in a time-dependent manner (0.5, 1, and 3 h). On the contrary, to investigate the effect of α-phellandrene on the cAMP signaling pathway, DPCs were preincubated with 50 μM of SQ22,536 for 1 h, treated with 12.5 μM of α-phellandrene, and further cultured for an additional 0.5 h. Total protein was extracted from the cells using a protein extraction buffer (iNtRON; Seoul, Korea); then, 15 μg of protein (determined by Bradford assay) was loaded onto separate lanes of 8% sodium dodecyl sulfate-polyacrylamide gel and electrophoresed. The proteins were electrotransferred to a nylon membrane (Amersham, Buckinghamshire, UK), and the membrane was blocked with bovine serum albumin (BSA; MP Biomedicals; Auckland, New Zealand) in Tris-buffered saline/Tween-20 (TBST) for 1 h at 25 °C, and incubated overnight at 4 °C with primary antibodies. The primary antibodies used were anti-PKA Cα (Cell Signaling; Herts, UK; 1:1000), anti-GAPDH (Cell Signaling; 1:1000), anti-phosphorylated CREB (pCREB; Cell Signaling; 1:1000), and anti-CREB (Cell Signaling; 1:1000). After incubation with peroxidase-conjugated secondary antibody (Sigma-Aldrich) for 1 h at 25 °C, the binding signals were visualized using an electrochemiluminescence detection reagent (Bio-Rad) on an EZ-capture (ATTO; Tokyo, Japan) and quantified using the ImageJ program (National Institutes of Health; Bethesda, MD, USA).

4.7. Quantification of VEGF Levels

DPCs (100,000 cells/well) were seeded in a 6-well plate and cultured with vehicle or 12.5 μM of α-phellandrene. When necessary, they were pretreated for 1 h with SQ22,536 before α-phellandrene treatment. After 48 h, the cell supernatants were collected, and the content of VEGF in the supernatants was measured using Human VEGF ELISA kit (Biolegend, CA, USA) with an M200 microplate reader (Tecan). The final VEGF levels were normalized to the total cellular protein content using the BCA Protein Assay Kit (Takara, Kyoto, Japan).

4.8. Statistical Analysis

Data are presented as mean ± standard error of the mean (SEM). The experimental conditions were compared using the two-tailed unpaired Student’s t-test using SPSS Statistics 26 (SPSS; Chicago, IL, USA). p < 0.05 was considered statistically significant.

5. Conclusions

In summary, we have demonstrated, for the first time, that α-phellandrene-mediated increased cAMP levels can enhance proliferation and elevate VEGF levels in DPCs. These findings not only highlight the essential role of cAMP in proliferation and VEGF regulation in DPCs, but also indicate the great potential of α-phellandrene for further developing hair loss treatments.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ijms23168959/s1.

Author Contributions

Conceptualization, S.P., W.K. and T.P.; formal analysis, S.P. and W.K.; data curation, S.P.; writing—original draft preparation, S.P., W.K., D.C. and B.S.; writing—review and editing, S.P., W.K. and T.P.; funding acquisition, T.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2022R1A2C100667511).

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

T.P. is the inventor of the patents (Korea Patent No. 10-2106712) and owns stocks in Botan icsens, Inc., which provides cosmetic products.

References

  1. Driskell, R.R.; Clavel, C.; Rendl, M.; Watt, F.M. Hair follicle dermal papilla cells at a glance. J. Cell Sci. 2011, 124, 1179–1182. [Google Scholar] [CrossRef] [PubMed]
  2. Rajendran, R.L.; Gangadaran, P.; Bak, S.S.; Oh, J.M.; Kalimuthu, S.; Lee, H.W.; Baek, S.H.; Zhu, L.; Sung, Y.K.; Jeong, S.Y. Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice. Sci. Rep. 2017, 7, 15560. [Google Scholar] [CrossRef] [PubMed]
  3. Koyama, T.; Kobayashi, K.; Hama, T.; Murakami, K.; Ogawa, R. Standardized scalp massage results in increased hair thickness by inducing stretching forces to dermal papilla cells in the subcutaneous tissue. Eplasty 2016, 16, e8. [Google Scholar]
  4. Itami, S.; Kurata, S.; Takayasu, S. Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factor-I from dermal papilla cells. Biochem. Biophys. Res. Commun. 1995, 212, 988–994. [Google Scholar] [CrossRef] [PubMed]
  5. Zhang, H.; Nan, W.; Wang, S.; Zhang, T.; Si, H.; Wang, D.; Yang, F.; Li, G. Epidermal growth factor promotes proliferation of dermal papilla cells via Notch signaling pathway. Biochimie 2016, 127, 10–18. [Google Scholar] [CrossRef]
  6. Iino, M.; Ehama, R.; Nakazawa, Y.; Iwabuchi, T.; Ogo, M.; Tajima, M.; Arase, S. Adenosine stimulates fibroblast growth factor-7 gene expression via adenosine A2b receptor signaling in dermal papilla cells. J. Investig. Dermatol. 2007, 127, 1318–1325. [Google Scholar] [CrossRef] [PubMed]
  7. Ami, S.; Rata, S.; Noda, T.; Kayasu, S. Interaction between dermal papilla cells and follicular epithelial cells in vitro: Effect of androgen. Br. J. Dermatol. 1995, 132, 527–532. [Google Scholar] [CrossRef]
  8. Zhang, X.; Wang, Y.; Gao, Y.; Liu, X.; Bai, T.; Li, M.; Li, L.; Chi, G.; Xu, H.; Liu, F. Maintenance of high proliferation and multipotent potential of human hair follicle-derived mesenchymal stem cells by growth factors. Int. J. Mol. Med. 2013, 31, 913–921. [Google Scholar] [CrossRef] [PubMed]
  9. Kim, B.H.; Lee, M.J.; Lee, W.-Y.; Pyo, J.; Shin, M.-S.; Hwang, G.S.; Shin, D.; Kim, C.E.; Park, E.-S.; Kang, K.S. Hair Growth Stimulation Effect of Centipeda minima Extract: Identification of Active Compounds and Anagen-Activating Signaling Pathways. Biomolecules 2021, 11, 976. [Google Scholar] [CrossRef] [PubMed]
  10. Madaan, A.; Verma, R.; Singh, A.T.; Jaggi, M. Review of hair follicle dermal papilla cells as in vitro screening model for hair growth. Int. J. Cosmet. Sci. 2018, 40, 429–450. [Google Scholar] [CrossRef] [PubMed]
  11. Bassino, E.; Gasparri, F.; Giannini, V.; Munaron, L. Paracrine crosstalk between human hair follicle dermal papilla cells and microvascular endothelial cells. Exp. Dermatol. 2015, 24, 388–390. [Google Scholar] [CrossRef] [PubMed]
  12. Woo, H.; Lee, S.; Kim, S.; Park, D.; Jung, E. Effect of sinapic acid on hair growth promoting in human hair follicle dermal papilla cells via Akt activation. Arch. Dermatol. Res. 2017, 309, 381–388. [Google Scholar] [CrossRef] [PubMed]
  13. Choi, Y.K.; Kang, J.-I.; Hyun, J.W.; Koh, Y.S.; Kang, J.-H.; Hyun, C.-G.; Yoon, K.-S.; Lee, K.S.; Lee, C.M.; Kim, T.Y. Myristoleic Acid Promotes Anagen Signaling by Autophagy through Activating Wnt/β-Catenin and ERK Pathways in Dermal Papilla Cells. Biomol. Ther. 2021, 29, 211. [Google Scholar] [CrossRef] [PubMed]
  14. Kang, J.-I.; Choi, Y.K.; Koh, Y.-S.; Hyun, J.-W.; Kang, J.-H.; Lee, K.S.; Lee, C.M.; Yoo, E.-S.; Kang, H.-K. Vanillic Acid Stimulates Anagen Signaling via the PI3K/Akt/β-Catenin Pathway in Dermal Papilla Cells. Biomol. Ther. 2020, 28, 354. [Google Scholar] [CrossRef] [PubMed]
  15. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schiöth, H.B.; Gloriam, D.E. Trends in GPCR drug discovery: New agents, targets and indications. Nat. Rev. Drug Discov. 2017, 16, 829–842. [Google Scholar] [CrossRef] [PubMed]
  16. Hauser, A.S.; Chavali, S.; Masuho, I.; Jahn, L.J.; Martemyanov, K.A.; Gloriam, D.E.; Babu, M.M. Pharmacogenomics of GPCR drug targets. Cell 2018, 172, 41–54. [Google Scholar] [CrossRef]
  17. Fredriksson, J.M.; Lindquist, J.M.; Bronnikov, G.E.; Nedergaard, J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J. Biol. Chem. 2000, 275, 13802–13811. [Google Scholar] [CrossRef]
  18. Nuamnaichati, N.; Sato, V.H.; Moongkarndi, P.; Parichatikanond, W.; Mangmool, S. Sustained β-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation. Life Sci. 2018, 193, 257–269. [Google Scholar] [CrossRef]
  19. Verhoeckx, K.C.; Doornbos, R.P.; Witkamp, R.F.; van der Greef, J.; Rodenburg, R.J. Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. Int. Immunopharmacol. 2006, 6, 419636. [Google Scholar] [CrossRef]
  20. Park, S.; Kang, W.; Choi, D.; Son, B.; Park, T. Nonanal Stimulates Growth Factors via Cyclic Adenosine Monophosphate (cAMP) Signaling in Human Hair Follicle Dermal Papilla Cells. Int. J. Mol. Sci. 2020, 21, 8054. [Google Scholar] [CrossRef]
  21. Tong, T.; Kim, M.; Park, T. α-Cedrene, a Newly Identified Ligand of MOR23, Increases Skeletal Muscle Mass and Strength. Mol. Nutr. Food Res. 2018, 62, 1800173. [Google Scholar] [CrossRef] [PubMed]
  22. Zhou, W.; Yu, L.; Fan, J.; Wan, B.; Jiang, T.; Yin, J.; Huang, Y.; Li, Q.; Yin, G.; Hu, Z. Endogenous parathyroid hormone promotes fracture healing by increasing expression of BMPR2 through cAMP/PKA/CREB pathway in mice. Cell. Physiol. Biochem. 2017, 42, 551–563. [Google Scholar] [CrossRef] [PubMed]
  23. Jeon, S.-H.; Chae, B.-C.; Kim, H.-A.; Seo, G.-Y.; Seo, D.-W.; Chun, G.-T.; Yie, S.-W.; Eom, S.-H.; Kim, P.-H. The PKA/CREB pathway is closely involved in VEGF expression in mouse macrophages. Mol. Cells (Springer Sci. Bus. Media BV) 2007, 23, 23–29. [Google Scholar]
  24. Saraswat, A.; Kumar, B. Minoxidil vs. finasteride in the treatment of men with androgenetic alopecia. Arch. Dermatol. 2003, 139, 1219–1221. [Google Scholar] [CrossRef]
  25. Adil, A.; Godwin, M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017, 77, 136–141. [Google Scholar] [CrossRef]
  26. Hu, R.; Xu, F.; Sheng, Y.; Qi, S.; Han, Y.; Miao, Y.; Rui, W.; Yang, Q. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: A randomized and comparative study in Chinese patients. Dermatol. Ther. 2015, 28, 303–308. [Google Scholar] [CrossRef]
  27. Lima, D.F.; Brandão, M.S.; Moura, J.B.; Leitão, J.M.; Carvalho, F.A.; Miúra, L.M.; Leite, J.R.; Sousa, D.P.; Almeida, F.R. Antinociceptive activity of the monoterpene α-phellandrene in rodents: Possible mechanisms of action. J. Pharm. Pharmacol. 2012, 64, 283–292. [Google Scholar] [CrossRef]
  28. Siqueira, H.D.A.S.; Neto, B.S.; Sousa, D.P.; Gomes, B.S.; da Silva, F.V.; Cunha, F.V.; Wanderley, C.W.; Pinheiro, G.; Cândido, A.G.; Wong, D.V. α-Phellandrene, a cyclic monoterpene, attenuates inflammatory response through neutrophil migration inhibition and mast cell degranulation. Life Sci. 2016, 160, 27–33. [Google Scholar] [CrossRef]
  29. İşcan, G.; Kırımer, N.; Demirci, F.; Demirci, B.; Noma, Y.; Başer, K.H.C. Biotransformation of (−)-(R)-α-phellandrene: Antimicrobial activity of its major metabolite. Chem. Biodivers. 2012, 9, 1525–1532. [Google Scholar] [CrossRef]
  30. De Christo Scherer, M.M.; Marques, F.M.; Figueira, M.M.; Peisino, M.C.O.; Schmitt, E.F.P.; Kondratyuk, T.P.; Endringer, D.C.; Scherer, R.; Fronza, M. Wound healing activity of terpinolene and α-phellandrene by attenuating inflammation and oxidative stress in vitro. J. Tissue Viability 2019, 28, 94–99. [Google Scholar] [CrossRef]
  31. Zhang, Q.; Liu, W.; Zhang, H.-M.; Xie, G.-Y.; Miao, Y.-R.; Xia, M.; Guo, A.-Y. hTFtarget: A comprehensive database for regulations of human transcription factors and their targets. Genom. Proteom. Bioinform. 2020, 18, 120–128. [Google Scholar] [CrossRef]
  32. Barrientos, S.; Stojadinovic, O.; Golinko, M.S.; Brem, H.; Tomic-Canic, M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008, 16, 585–601. [Google Scholar] [CrossRef] [PubMed]
  33. Halmos, T.; Suba, I. The physiological role of growth hormone and insulin-like growth factors. Orv. Hetil. 2019, 160, 1774–1783. [Google Scholar] [CrossRef] [PubMed]
  34. Fernandes-Freitas, I.; Owen, B.M. Metabolic roles of endocrine fibroblast growth factors. Curr. Opin. Pharmacol. 2015, 25, 30–35. [Google Scholar] [CrossRef] [PubMed]
  35. Goodman, L.V.; Ledbetter, S.R. Secretion of stromelysin by cultured dermal papilla cells: Differential regulation by growth factors and functional role in mitogen-induced cell proliferation. J. Cell. Physiol. 1992, 151, 41–49. [Google Scholar] [CrossRef] [PubMed]
  36. Heyneman, C.A.; Lawless-Liday, C.; Wall, G.C. Oral versus topical NSAIDs in rheumatic diseases. Drugs 2000, 60, 555–574. [Google Scholar] [CrossRef] [PubMed]
  37. Fang, J.-Y.; Liu, P.-F.; Huang, C.-M. Decreasing systemic toxicity via transdermal delivery of anticancer drugs. Curr. Drug Metab. 2008, 9, 592–597. [Google Scholar] [CrossRef]
  38. Aqil, F.; Munagala, R.; Jeyabalan, J.; Vadhanam, M.V. Bioavailability of phytochemicals and its enhancement by drug delivery systems. Cancer Lett. 2013, 334, 133–141. [Google Scholar] [CrossRef] [PubMed]
  39. Bos, J.D.; Meinardi, M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp. Dermatol. Viewp. 2000, 9, 165–169. [Google Scholar] [CrossRef]
  40. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef] [PubMed]
  41. Kang, W.; Choi, D.; Park, T. Decanal Protects against UVB-Induced Photoaging in Human Dermal Fibroblasts via the cAMP Pathway. Nutrients 2020, 12, 1214. [Google Scholar] [CrossRef]
  42. Vilardaga, J.-P.; Jean-Alphonse, F.G.; Gardella, T.J. Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 2014, 10, 700–706. [Google Scholar] [CrossRef] [PubMed]
  43. Filardo, E.J.; Quinn, J.A.; Frackelton, A.R., Jr.; Bland, K.I. Estrogen action via the G protein-coupled receptor, GPR30: Stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol. Endocrinol. 2002, 16, 70–84. [Google Scholar] [CrossRef]
  44. Daina, A.; Michielin, O.; Zoete, V. SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019, 47, W357–W364. [Google Scholar] [CrossRef] [PubMed]
  45. Awale, M.; Reymond, J.-L. The polypharmacology browser: A web-based multi-fingerprint target prediction tool using ChEMBL bioactivity data. J. Chem. 2017, 9, 11. [Google Scholar] [CrossRef] [PubMed]
  46. Awale, M.; Reymond, J.-L. Polypharmacology browser PPB2: Target prediction combining nearest neighbors with machine learning. J. Chem. Inf. Model. 2018, 59, 10–17. [Google Scholar] [CrossRef]
  47. Grant, M.B.; Davis, M.I.; Caballero, S.; Feoktistov, I.; Biaggioni, I.; Belardinelli, L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A2B adenosine receptor stimulation. Investig. Ophthalmol. Vis. Sci. 2001, 42, 2068–2073. [Google Scholar]
  48. Turner, N.A.; Porter, K.E.; Smith, W.H.; White, H.L.; Ball, S.G.; Balmforth, A.J. Chronic β2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc. Res. 2003, 57, 784–792. [Google Scholar] [CrossRef]
  49. Coronas, V.; Bantubungi, K.; Fombonne, J.; Krantic, S.; Schiffmann, S.N.; Roger, M. Dopamine D3 receptor stimulation promotes the proliferation of cells derived from the post-natal subventricular zone. J. Neurochem. 2004, 91, 1292–1301. [Google Scholar] [CrossRef] [PubMed]
  50. Yokoyama, U.; Patel, H.H.; Lai, N.C.; Aroonsakool, N.; Roth, D.M.; Insel, P.A. The cyclic AMP effector Epac integrates pro- and anti-fibrotic signals. Proc. Natl. Acad. Sci. USA 2008, 105, 6386–6391. [Google Scholar] [CrossRef] [PubMed]
  51. Perez-Aso, M.; Fernandez, P.; Mediero, A.; Chan, E.S.; Cronstein, B.N. Adenosine 2A receptor promotes collagen production by human fibroblasts via pathways involving cyclic AMP and AKT but independent of Smad2/3. FASEB J. 2014, 28, 802–812. [Google Scholar] [CrossRef]
  52. Parker, D.; Ferreri, K.; Nakajima, T.; LaMorte, V.; Evans, R.; Koerber, S.; Hoeger, C.; Montminy, M. Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol. Cell. Biol. 1996, 16, 694–703. [Google Scholar] [CrossRef] [PubMed]
  53. Xu, W.; Kasper, L.H.; Lerach, S.; Jeevan, T.; Brindle, P.K. Individual CREB-target genes dictate usage of distinct cAMP-responsive coactivation mechanisms. EMBO J. 2007, 26, 2890–2903. [Google Scholar] [CrossRef] [PubMed]
  54. Siu, Y.T.; Jin, D.Y. CREB− a real culprit in oncogenesis. FEBS J. 2007, 274, 3224–3232. [Google Scholar] [CrossRef] [PubMed]
  55. Cha-Molstad, H.; Keller, D.M.; Yochum, G.S.; Impey, S.; Goodman, R.H. Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proc. Natl. Acad. Sci. USA 2004, 101, 13572–13577. [Google Scholar] [CrossRef] [PubMed]
  56. Martianov, I.; Choukrallah, M.-A.; Krebs, A.; Ye, T.; Legras, S.; Rijkers, E.; Van Ijcken, W.; Jost, B.; Sassone-Corsi, P.; Davidson, I. Cell-specific occupancy of an extended repertoire of CREM and CREB binding loci in male germ cells. BMC Genom. 2010, 11, 530. [Google Scholar] [CrossRef] [PubMed]
  57. Zhang, X.; Odom, D.T.; Koo, S.-H.; Conkright, M.D.; Canettieri, G.; Best, J.; Chen, H.; Jenner, R.; Herbolsheimer, E.; Jacobsen, E. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc. Natl. Acad. Sci. USA 2005, 102, 4459–4464. [Google Scholar] [CrossRef] [PubMed]
  58. Lachgar, S.; Moukadiri, H.; Jonca, F.; Charveron, M.; Bouhaddioui, N.; Gall, Y.; Bonafe, J.L.; Plouët, J. Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells. J. Investig. Dermatol. 1996, 106, 17–23. [Google Scholar] [CrossRef] [PubMed]
  59. Yano, K.; Brown, L.F.; Detmar, M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J. Clin. Investig. 2001, 107, 409–417. [Google Scholar] [CrossRef]
  60. Li, W.; Man, X.-Y.; Li, C.-M.; Chen, J.-Q.; Zhou, J.; Cai, S.-Q.; Lu, Z.-F.; Zheng, M. VEGF induces proliferation of human hair follicle dermal papilla cells through VEGFR-2-mediated activation of ERK. Exp. Cell Res. 2012, 318, 1633–1640. [Google Scholar] [CrossRef]
  61. Lee, E.; Choi, E.J.; Kim, J.; Hwang, Y.; Kim, C.D.; Lee, M.; Roh, S.; Kim, Y.; Han, I.; Kang, S. Malva verticillata seed extracts upregulate the Wnt pathway in human dermal papilla cells. Int. J. Cosmet. Sci. 2016, 38, 148–154. [Google Scholar] [CrossRef] [PubMed]
  62. Junlatat, J.; Sripanidkulchai, B. Hair Growth-Promoting Effect of Carthamus tinctorius Floret Extract. Phytother. Res. 2014, 28, 1030–1036. [Google Scholar] [CrossRef] [PubMed]
  63. Rho, S.-S.; Park, S.-J.; Hwang, S.-L.; Lee, M.-H.; Kim, C.D.; Lee, I.-H.; Chang, S.-Y.; Rang, M.-J. The hair growth promoting effect of Asiasari radix extract and its molecular regulation. J. Dermatol. Sci. 2005, 38, 89–97. [Google Scholar] [CrossRef] [PubMed]
  64. Messenger, A.; Rundegren, J. Minoxidil: Mechanisms of action on hair growth. Br. J. Dermatol. 2004, 150, 186–194. [Google Scholar] [CrossRef] [PubMed]
  65. Stork, P.J.; Schmitt, J.M. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 2002, 12, 258–266. [Google Scholar] [CrossRef]
  66. Yamaguchi, T.; Pelling, J.C.; Ramaswamy, N.T.; Eppler, J.W.; Wallace, D.P.; Nagao, S.; Rome, L.A.; Sullivan, L.P.; Grantham, J.J. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000, 57, 1460–1471. [Google Scholar] [CrossRef] [PubMed]
  67. Hänel, K.H.; Cornelissen, C.; Lüscher, B.; Baron, J.M. Cytokines and the skin barrier. Int. J. Mol. Sci. 2013, 14, 6720–6745. [Google Scholar] [CrossRef] [PubMed]
  68. Carrasco, E.; Soto-Heredero, G.; Mittelbrunn, M. The role of extracellular vesicles in cutaneous remodeling and hair follicle dynamics. Int. J. Mol. Sci. 2019, 20, 2758. [Google Scholar] [CrossRef]
Ijms 23 08959 g001 550
Figure 1. α-phellandrene increases cyclic adenosine monophosphate (cAMP) levels in dermal papilla cells (DPCs). (A) The structure of α-phellandrene. (B,C) Total cAMP content was measured in DPCs after 30 min stimulation with vehicle (dimethyl sulfoxide; DMSO) or various concentrations of α-phellandrene or forskolin. Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments.
Figure 1. α-phellandrene increases cyclic adenosine monophosphate (cAMP) levels in dermal papilla cells (DPCs). (A) The structure of α-phellandrene. (B,C) Total cAMP content was measured in DPCs after 30 min stimulation with vehicle (dimethyl sulfoxide; DMSO) or various concentrations of α-phellandrene or forskolin. Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments.
Ijms 23 08959 g001
Ijms 23 08959 g002 550
Figure 2. α-phellandrene promotes cell proliferation in dermal papilla cells (DPCs). DPCs were cultured for 24, 48, and 72 h with vehicle (dimethyl sulfoxide; DMSO) as a control (Con), five different α-phellandrene concentrations (6.25, 12.5, 25, 50, and 100 µM), or 10 µM forskolin (Fsk). Cell proliferation was measured using a water-soluble tetrazolium salt (WST-1). Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as * p < 0.05 and ** p < 0.01, *** p < 0.001 vs. control (Con).
Figure 2. α-phellandrene promotes cell proliferation in dermal papilla cells (DPCs). DPCs were cultured for 24, 48, and 72 h with vehicle (dimethyl sulfoxide; DMSO) as a control (Con), five different α-phellandrene concentrations (6.25, 12.5, 25, 50, and 100 µM), or 10 µM forskolin (Fsk). Cell proliferation was measured using a water-soluble tetrazolium salt (WST-1). Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as * p < 0.05 and ** p < 0.01, *** p < 0.001 vs. control (Con).
Ijms 23 08959 g002
Ijms 23 08959 g003 550
Figure 3. α-phellandrene-mediated cyclic adenosine monophosphate (cAMP) accumulation stimulates the downstream protein kinase (PKA)/cAMP-responsive element-binding protein (CREB) signaling in dermal papilla cells (DPCs). DPCs were treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM α-phellandrene for 0.5, 1, and 3 h, following which (A) protein kinase A catalytic subunit (PKA Cα) expression and (B) CREB phosphorylation were quantified by western blotting. Cells were incubated with either vehicle or 12.5 μM of α-phellandrene for 0.5 h. The cells were preincubated with the vehicle or 50 μM of SQ22,536 (cAMP inhibitor) for 1 h before α-phellandrene treatment. (C) PKA Cα expression and (D) CREB phosphorylation were quantified by western blotting. Relative PKA Cα protein expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) level and the ratio of CREB phosphorylation normalized to total CREB is shown (p-CREB/CREB). Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05; ** p < 0.01.
Figure 3. α-phellandrene-mediated cyclic adenosine monophosphate (cAMP) accumulation stimulates the downstream protein kinase (PKA)/cAMP-responsive element-binding protein (CREB) signaling in dermal papilla cells (DPCs). DPCs were treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM α-phellandrene for 0.5, 1, and 3 h, following which (A) protein kinase A catalytic subunit (PKA Cα) expression and (B) CREB phosphorylation were quantified by western blotting. Cells were incubated with either vehicle or 12.5 μM of α-phellandrene for 0.5 h. The cells were preincubated with the vehicle or 50 μM of SQ22,536 (cAMP inhibitor) for 1 h before α-phellandrene treatment. (C) PKA Cα expression and (D) CREB phosphorylation were quantified by western blotting. Relative PKA Cα protein expression was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) level and the ratio of CREB phosphorylation normalized to total CREB is shown (p-CREB/CREB). Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05; ** p < 0.01.
Ijms 23 08959 g003
Ijms 23 08959 g004 550
Figure 4. α-phellandrene promotes cell proliferation via the cyclic adenosine monophosphate (cAMP) signaling pathway. Cells were incubated with either vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 48 h. The cells were preincubated with the vehicle, 50 μM of SQ22,536, 10 μM of H89 (protein kinase A inhibitor), or 100 nM of 666-15 (cAMP-responsive element-binding protein inhibitor) for 1 h before α-phellandrene treatment. (A–C) Cell proliferation was measured using water-soluble tetrazolium salt (WST-1) analysis. Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05; ** p < 0.01.
Figure 4. α-phellandrene promotes cell proliferation via the cyclic adenosine monophosphate (cAMP) signaling pathway. Cells were incubated with either vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 48 h. The cells were preincubated with the vehicle, 50 μM of SQ22,536, 10 μM of H89 (protein kinase A inhibitor), or 100 nM of 666-15 (cAMP-responsive element-binding protein inhibitor) for 1 h before α-phellandrene treatment. (A–C) Cell proliferation was measured using water-soluble tetrazolium salt (WST-1) analysis. Results are expressed as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05; ** p < 0.01.
Ijms 23 08959 g004
Ijms 23 08959 g005 550
Figure 5. α-phellandrene increases vascular endothelial growth factor (VEGF) gene expression in dermal papilla cells (DPCs). (A) DPCs were either treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 6 h. Then, mRNA was extracted and quantitative polymerase chain reaction (qPCR) analyses were performed for detecting the altered expression of eighteen growth factor genes as potential target genes of cAMP-responsive element-binding (CREB) protein. Data were normalized relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in each sample and expressed relative to the control value (vehicle). Gene abbreviations are as follows: bone morphogenetic protein 1 (BMP1), colony stimulating factor 1(CSF1), fibroblast growth factor 1 (FGF1), fibroblast growth factor 11 (FGF11), glial cell derived neurotrophic factor (GDNF), glucose-6-phosphate isomerase (GPI), heparin binding epidermal growth factor- like growth factor (HBEGF), insulin-like growth factor 1 (IGF1), inhibin subunit beta A (INHBA), notch ligand jagged-1 (JAG1), midkine (MDK), nerve growth factor (NGF), neurotrophin 3 (NTF3), neuregulin 1 (NRG1), platelet derived growth factor C (PDGFC), secreted phosphoprotein 1 (SPP1), transforming growth factor beta 1 (TGFB1), and VEGF. The red box indicates the significantly upregulated gene in response to α-phellandrene treatment. (B) DPCs were either treated with vehicle or 12.5 μM of α-phellandrene and incubated for a variety of times (3, 6, and 12 h). Then VEGF mRNA expression was analyzed. Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as * p < 0.05.
Figure 5. α-phellandrene increases vascular endothelial growth factor (VEGF) gene expression in dermal papilla cells (DPCs). (A) DPCs were either treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 6 h. Then, mRNA was extracted and quantitative polymerase chain reaction (qPCR) analyses were performed for detecting the altered expression of eighteen growth factor genes as potential target genes of cAMP-responsive element-binding (CREB) protein. Data were normalized relative to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in each sample and expressed relative to the control value (vehicle). Gene abbreviations are as follows: bone morphogenetic protein 1 (BMP1), colony stimulating factor 1(CSF1), fibroblast growth factor 1 (FGF1), fibroblast growth factor 11 (FGF11), glial cell derived neurotrophic factor (GDNF), glucose-6-phosphate isomerase (GPI), heparin binding epidermal growth factor- like growth factor (HBEGF), insulin-like growth factor 1 (IGF1), inhibin subunit beta A (INHBA), notch ligand jagged-1 (JAG1), midkine (MDK), nerve growth factor (NGF), neurotrophin 3 (NTF3), neuregulin 1 (NRG1), platelet derived growth factor C (PDGFC), secreted phosphoprotein 1 (SPP1), transforming growth factor beta 1 (TGFB1), and VEGF. The red box indicates the significantly upregulated gene in response to α-phellandrene treatment. (B) DPCs were either treated with vehicle or 12.5 μM of α-phellandrene and incubated for a variety of times (3, 6, and 12 h). Then VEGF mRNA expression was analyzed. Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as * p < 0.05.
Ijms 23 08959 g005
Ijms 23 08959 g006 550
Figure 6. The inhibition of the cyclic adenosine monophosphate (cAMP) pathway blocks the effect of α-phellandrene on vascular endothelial growth factor (VEGF) production. (A,B) Dermal papilla cells (DPCs) were either treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 6 h (for mRNA analysis) or 24 h (for protein analysis) and pretreated with vehicle or 50 μM of SQ22,536 (cAMP inhibitor) for 1 h before α-phellandrene treatment. Then the mRNA was extracted and qPCR analyses were performed for VEGF expression changes. Each sample’s mRNA level was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed relative to the value of the control (vehicle). The VEGF protein levels were normalized to the total amount of cellular protein. Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05.
Figure 6. The inhibition of the cyclic adenosine monophosphate (cAMP) pathway blocks the effect of α-phellandrene on vascular endothelial growth factor (VEGF) production. (A,B) Dermal papilla cells (DPCs) were either treated with vehicle (dimethyl sulfoxide; DMSO) or 12.5 μM of α-phellandrene for 6 h (for mRNA analysis) or 24 h (for protein analysis) and pretreated with vehicle or 50 μM of SQ22,536 (cAMP inhibitor) for 1 h before α-phellandrene treatment. Then the mRNA was extracted and qPCR analyses were performed for VEGF expression changes. Each sample’s mRNA level was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and expressed relative to the value of the control (vehicle). The VEGF protein levels were normalized to the total amount of cellular protein. Results are shown as mean ± standard error of the mean (SEM) of three independent experiments. Statistically significant differences are marked as ns, not significant (p > 0.05); * p < 0.05.
Ijms 23 08959 g006
Ijms 23 08959 g007 550
Figure 7. Schematic illustration of the molecular mechanism of α-phellandrene-mediated dermal papilla cell (DPC) proliferation. α-phellandrene activated the cyclic adenosine monophosphate (cAMP) signaling and increased vascular endothelial growth factor (VEGF) expression, thereby promoting DPC proliferation.
Figure 7. Schematic illustration of the molecular mechanism of α-phellandrene-mediated dermal papilla cell (DPC) proliferation. α-phellandrene activated the cyclic adenosine monophosphate (cAMP) signaling and increased vascular endothelial growth factor (VEGF) expression, thereby promoting DPC proliferation.
Ijms 23 08959 g007
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Kang, W.; Park, S.; Choi, D.; Son, B.; Park, T. Activation of cAMP Signaling in Response to α-Phellandrene Promotes Vascular Endothelial Growth Factor Levels and Proliferation in Human Dermal Papilla Cells. Int. J. Mol. Sci. 2022, 23, 8959. https://doi.org/10.3390/ijms23168959

AMA Style

Kang W, Park S, Choi D, Son B, Park T. Activation of cAMP Signaling in Response to α-Phellandrene Promotes Vascular Endothelial Growth Factor Levels and Proliferation in Human Dermal Papilla Cells. International Journal of Molecular Sciences. 2022; 23(16):8959. https://doi.org/10.3390/ijms23168959

Chicago/Turabian Style

Kang, Wesuk, Soyoon Park, Dabin Choi, Bomin Son, and Taesun Park. 2022. "Activation of cAMP Signaling in Response to α-Phellandrene Promotes Vascular Endothelial Growth Factor Levels and Proliferation in Human Dermal Papilla Cells" International Journal of Molecular Sciences 23, no. 16: 8959. https://doi.org/10.3390/ijms23168959

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop